CHATSWORTH, Calif., May 25, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables and a provider of high-value personalized diagnostics, today announced that the company will be presenting at two upcoming investor conferences.
On Wednesday, May 30, 2012, Cesar M. Garcia, IRIS' Chairman, President and Chief Executive Officer and Amin Khalifa, IRIS' Chief Financial Officer will participate in the 9th Annual Craig-Hallum Institutional Investor Conference in Minneapolis.
On Thursday, June 7, 2012, Amin Khalifa, IRIS' Chief Financial Officer will give a presentation at the Jefferies 2012 Global Healthcare Conference in New York City. Mr. Khalifa, along with Yvonne Briggs, Vice President of Corporate Development, will be available for one-on-one meetings with institutional and accredited investors at the conference throughout the day.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,700 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets, including applications in hematology and body fluids. In addition, the Company's personalized medicine group has a high complexity CLIA-certified laboratory for the further development and commercialization of the Company's NADiA ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.